Your vote is important!
Please be sure to vote your shares online now or by phone by calling 800-454-8683.
Sensei Biotherapeutics is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. Sensei is headquartered in Rockville, MD, with an office in Boston, MA.
Powered by Donnelley Financial Solutions
Copyright ©
Mediant Communications Inc.
All Rights Reserved.